Friday, 20 Oct 2017

You are here

Novel Gel Drug Delivery Developed for Rheumatoid Arthritis

Scientists at the Institute for Basic Science have invented a hydrogel capable of delivering drug at sites of inflammation in disorders such as rheumatoid arthritis. Published in Advanced Materials, this jelly-like material could be used to absorb extra fluids in swelling joints and release drugs wherever nitric oxide is produced in abundance.

Nitric oxide (NO) is produced withing inflamed joints and mediates many of the functions that augment rheumaatoid inflammation. This new hydrogel targets NO, a transient gas 

The polymeric acrylamide hydrogel has little toxicity, can absorb a large amount of water and has a NO cross-linking agent (NOCCL) forms bridges between the acrylamide molecules creating a net, which can trap drug molecules inside. When NO cleaves the NOCCL bridges, the gel changes its structure, frees the drug and absorbs new liquid.

In this study researchers showed that the NOCCL crosslinking agent can selectively and sensitively react with NO. The next step is to use a nano-sized hydrogel in a RA mouse model.

These hydrogels could be useful for other diseases characterized by overexpression of NO, or maybe even as environmental sensors, since NO is also a polluting gas emitted in vehicle exhaust.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Rheumatologists are Slow to Change DMARDs

The paradigm of rheumatoid arthritis (RA) therapy mandates early diagnosis and aggressive treatment.  Yet a recent cohort study has shown that RA patients with moderate to high disease activity (MHDAS) were met with infrequent DMARD adjustments; with median time to DMARD adjustment being 5 months and median time to low disease activity (LDAS) was roughly 10 months. 

2016 EULAR Guidelines on RA Management

The management of rheumatoid arthritis (RA) has evolved significantly with time.  Nevertheless, there are still some uncertainties - such as when, what and which biologic or novel therapy should be used.

New EULAR Guidelines for Ultrasound Use

In the current issue of ARD, the European League Against Rheumatism (EULAR) has revised and updated its 2001 guideline for musculoskeletal (MS) ultrasound (US) in rheumatology; this time incorporating new advances, technological developments and use indications in rheumatology. EULAR has provided this as an educational tool and standard reference for MSUS practice and research in rheumatology.

The Unregulated $37 Billion Supplement Industry

In 1994 there were 600 supplement companies, producing 4,000 OTC supplement products for a total revenue of about $4 billion. Today we have close to 6,000 companies, producting nearly 75,000 supplement products, bringing in $37 billion annually.  And all of this is regulated by 26 people and a budget of $5 million at the FDA.

Curbside Consults - July 2017

Curbside Consults are cases submitted by our rheumatology colleagues as challenging therapeutic or safety issues. Answers are based on experience, with added evidence from the medical literature and published guidelines. Here are four new cases.